skip to main content

1.2B4

1.2B4

Catalogue No.

10070103

Cell Line Name

1.2B4

Cell Line Description

1.2B4 is a hybrid cell line formed by the electrofusion of a primary culture of human pancreatic islets with HuP-T3, a human pancreatic carcinoma cell line (ECACC catalogue number 93121055). 1.2B4 has been shown to be tumourigenic when transplanted into a SCID mouse host. The cell line has applications in the study of pancreatic cell biology. 1.2B4 cells provide a method of producing pure insulin secreting cells when stimulated (please see attached protocols for the stimulation of insulin secretion).. This is an alternative to the use of primary tissue in cell transplantation therapies for type 1 diabetes.

 

Based on evidence from customer feedback we cannot guarantee the cells will produce insulin.

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

Not specified

Products

1.2B4 cells have been shown to express insulin, glucokinase and IAPP by immunocytochemistry. These cells express the GLUT1 glucose transporter.

Tissue of Origin

Pancreatic islets

DNA profile (STR Profile)

Amelogenin: X,Y
CSF1PO: 10
D5S818: 10,14
D7S820: 12
D13S317: 9,11
D16S539: 10,13
TH01: 9
TPOX: 8,12
vWA: 18

Karyotype

Modal chromosome number 67-71

Disease

None Stated

Culture Conditions

Cell Type

Epitheloid

Subculture Routine

Split sub-confluent cultures (70-80%) 1:2 to 1:6 i.e. seeding at 2-4 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Population doubling approx 20hrs. At confluence 10⁵ cells/cm² can be expected.

Culture Medium

RPMI-1640 + 2mM Glutamine + 10% FCS

Growth Mode

Adherent

Additional Info

Depositor

Professor Peter R Flatt, Head of Diabetes Research Group, School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Northern Ireland BT52 1SA.

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Nishimura N et. al., (1993) Newly established human pancreatic carcinoma cell lines and their lectin binding properties Int J Pancreatol 13: 31-41 PMID: 8454916.

Bibliography

Guo-Parke H, McCluskey JT, Kelly C, Hamid M, McClenaghan NH, Flatt PR.2012. Configuration of electrofusion-derived human insulin-secreting cell line as pseudoislets enhances functionality and therapeutic utility. J Endocrinol. 214(3):257-65. PMID: 22685334

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: 1.2B4 (ECACC 10070103).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.